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Interleukin- (IL-) 37 is a novel anti-inflammatory cytokine that suppresses immune response and inflammation. This study was
performed to determine whether IL-37 was elevated in patients with rheumatoid arthritis (RA) and investigate the correlation
between IL-37 level and disease activity and the concentration of Th1/Th2/Th17-related cytokines. Clinical parameters of disease
activity, including the 28-joint disease activity score (DAS28) and C-reactive protein (CRP), were collected in 34 RA patients
and 34 age- and sex-matched healthy controls. Plasma IL-37 was measured by ELISA. Plasma levels of TNF-𝛼, IL-1𝛽, IL-2, IL-
4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-CSF, IFN-𝛾, MCP-1, and MIP-1𝛽 were analyzed using the Bio-Plex
suspension array system. It was found that IL-37 levels were elevated markedly in RA patients and almost undetectable in healthy
controls. In addition, IL-37 levels in patients with active RA were significantly enhanced as compared with those in patients of
remission. More importantly, IL-37 showed a significant correlation with disease activity (DAS28) and IL-4, IL-7, IL-10, IL-12, and
IL-13 concentrations in RA patients. These findings suggest that IL-37 plays an important role in the pathogenesis of RA and may
prove to be a potential biomarker of active RA.
1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune inflam-
matory disorder primarily affecting the peripheral joints.The
exact pathogenesis of RA remains elusive, though strong
evidence suggests the involvement of cytokines in the disease
progression. It is clear that cytokines play a fundamental
role in various inflammatory processes, articular destruction,
and RA-associated comorbidities [1]. Single-cytokine target
therapies such as TNF blockade have proved useful for the
treatment of RA patients [2]. However, nonresponders or
partial clinical responders are not infrequently seen and
disease often flares up upon discontinuation of treatment.
Thus, considerable unmet clinical needs remain, and biology
and relevant pathophysiology of novel cytokines in RA need
to be further explored.
Recent studies have shown that IL-37 is a key cytokine
in regulating inflammatory response, mainly by inhibiting
the expression, production, and function of proinflammatory
cytokines. IL-37, formerly named IL-1F7, shares similar struc-
tural pattern to the IL-1 family. IL-37 is widely expressed in
several types of cells, organs, and tissues, including mono-
cytes, plasma cells, dendritic cells, the testis, thymus, and
uterus. IL-37 is believed to play potential roles in autoimmune
diseases by suppressing immune responses and inflamma-
tion. Immunohistochemistry staining on the synovial tissue
from individuals with active RA demonstrated the presence
of large amounts of IL-37 in the diseased synovial lining [3].
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Numerous cytokines, both proinflammatory and anti-
inflammatory, have been detected in RA patients, and the
balance between the activities of these opposing cytokines
determines disease severity [4]. An imbalance between pro-
and anti-inflammatory cytokine activities favors the induc-
tion of autoimmunity, chronic inflammation, and thereby
joint damage [5]. Given the correlation between cytokines
and disease symptoms of RA patients, some Th1/Th2/Th17-
related cytokines or multicytokine profiles were detected as
the important biomarkers for RA patients [6].
In the present study, we sought to see whether plasma IL-
37 was elevated in RA patients and whether it was correlated
with the disease activity.The relationship between IL-37 level
and multiple Th1/Th2/Th17-related cytokine concentrations
was also investigated.
2. Materials and Methods
2.1. Subjects and Clinical Assessment. This study was con-
ducted in 34 RA patients who visited the Department of
Rheumatology at Changhai Hospital between July 2011 and
June 2012 and fulfilled the American College of Rheumatol-
ogy (ACR) 1987 revised criteria for the classification of RA.
Additional 34 age- and sex-matched healthy adults without
any evidence of chronic inflammatory disease served as
controls. This study was approved by the Ethics Committee
of Changhai Hospital, and all study subjects signed written
informed consent before participation in the study.
The baseline number of tender or swollen joints was
calculated using the 28-joint disease activity score (DAS28);
the erythrocyte sedimentation rate (ESR) was recorded; and
the severity of pain reported by each patient was assessed
using the pain visual analogue scale (VAS). Based on the
DAS28 results, the 34 RA patients were subdivided into four
groups: remission (DAS28 ≤ 2.6), mild (2.6 < DAS28 ≤ 3.2),
moderate (3.2 < DAS28 ≤ 5.1), and severe (5.1 < DAS28).
At the time of clinical assessment for disease activity, blood
samples were collected for C-reactive protein (CRP) and
cytokine level measurement.
2.2. Measurement of IL-37 Level. Plasma samples were col-
lected intravenously, centrifuged (2,500×g for 10min at 4∘C),
and stored at −20∘C until analysis. The plasma concentration
of IL-37 was measured using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (AdipoGen, San Diego,
CA, USA).
2.3. Determination of Th1/Th2/Th17-Related Cytokine Con-
centrations. The following cytokines were measured simul-
taneously using a 17-plex test kit: TNF-𝛼, IL-1𝛽, IL-2, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-
CSF, IFN-𝛾, MCP-1, and MIP-1𝛽, broadly representative of
Th1/Th2/Th17-related cytokines. These were measured using
the Bio-Plex suspension array system (Bio-Rad Laborato-
ries Inc., Hercules, CA, USA) that utilizes Luminex xMAP
multiplex technology to enable simultaneous detection and
quantitation of multiple different analytes in a single sample.
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Figure 1: Plasma IL-37 levels in patients with rheumatoid arthritis.
At the time of recruitment, 19 patients were assessed as having
active joint disease and the remaining 15 patients were in remission
according to DAS28 scoring. At the time of clinical assessment for
disease activity, blood samples were collected and plasma IL-37 was
determined using a commercial ELISA kit. Data are expressed as
the mean ± SEM. ∗𝑃 < 0.05 compared to the patients with RA in
remission.
2.4. Statistical Analysis. Data analyses were performed with
SPSS version 16.0. All descriptive variables were expressed
as the mean (±SEM) or medium. Comparisons between two
groups were performed using Student’s 𝑡-test or nonpara-
metric Mann-Whitney 𝑈 test. The correlations between the
concentration of each cytokine and DAS28 and CRP level
were tested using Pearson’s correlation test. For all tests, 𝑃
values less than 0.05 were considered statistically significant.
3. Results
3.1. Clinical Characteristics of the Study Subjects. Recruited
in this study were 34 Chinese RA patients (29 females and
5 males) with a median age of 56 years (range 33–82) and
a mean duration of RA exceeding 10 years. At the time of
recruitment, 19 patients were assessed as having active joint
disease and the remaining 15 patients were in remission
according to DAS28 scoring. The healthy controls had a
median age of 53 years (range 28–76).Therewas no significant
difference in age between the two groups (Table 1).
3.2. Correlation between IL-37 Level and Disease Activity.
The plasma concentration of IL-37 was undetectable in the
healthy controls (data not shown), while it was elevated
markedly in the RA patients. Furthermore, IL-37 levels in
patientswith activeRAwere significantly higher than those in
patients of remission (Figure 1). In addition, IL-37 levels were
significantly correlated with DAS28 disease activity scores.
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Table 1: Clinical characteristics of the study subjects.
Character Medium (range)
Inactive RA patients (𝑛 = 15) Active RA patients (𝑛 = 19) Healthy controls (𝑛 = 34)
Age (yrs) 54 (33–82) 60 (35–78) 53 (28–76)
Gender (male/female) 4/11 1/18 6/28
Disease duration (yrs) 6 (0.25–30) 9 (0.5–27) —
Swollen joint count 0 (0-0) 0 (0–20) —
Tender joint count 0 (0-0) 0 (0–25) —
Patient VAS 30 (10–60) 70 (30–80) —
ESR (mm/h) 12 (2–21) 67 (7–110) —
CRP (mg/L) 2.86 (1.07–18.80) 21.35 (1.85–47.10) —
DAS28 2.16 (1.19–2.54) 5.75 (2.66–8.34) —
Remission (DAS28 ≤ 2.6) (𝑛) 15 — —
Mild (2.6 < DAS28 ≤ 3.2) (𝑛) — 3 —
Moderate (3.2 < DAS28 ≤ 5.1) (𝑛) — 3 —
Severe (5.1 < DAS28) (𝑛) — 13 —
DAS28, disease activity score 28; VAS, visual analogue scale; NS, not significant.
Table 2: Correlations between IL-37 and DAS28, CRP, and
Th1/Th2/Th17-related cytokines in patients with rheumatoid arthri-
tis.
Coefficient 𝑃
DAS28 0.348∗ 0.044
CRP 0.196 0.273
TNF-𝛼 0.262 0.148
IL-1𝛽 0.272 0.133
IL-2 0.290 0.108
IL-4 0.362∗ 0.042
IL-5 0.310 0.085
IL-6 0.227 0.212
IL-7 0.526∗∗ 0.002
IL-8 −0.028 0.878
IL-10 0.395∗ 0.025
IL-12 0.451∗∗ 0.010
IL-13 0.472∗∗ 0.006
IL-17 0.096 0.600
G-CSF 0.319 0.075
GM-CSF 0.261 0.149
IFN-𝛾 0.328 0.067
MCP-1 0.321 0.073
MIP-1𝛽 −0.269 0.137
Pearson’s correlation test was used for statistical analysis. ∗𝑃 value less than
0.05. ∗∗𝑃 value less than 0.01.
However, no significant correlation between IL-37 level and
CRP concentration was observed in our study (Table 2).
3.3. Correlations between IL-37 and Th1/Th2/Th17-Related
Cytokines. Of the 17Th1/Th2/Th17-related cytokines, TNF-𝛼,
IL-1𝛽, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, GM-CSF, IFN-𝛾, and
MCP-1 in the blood of RA patients were positively correlated
with the DAS28 disease activity score (Table 3). The IL-37
Table 3: Correlations between plasma Th1/Th2/Th17-related
cytokines and DAS28 in patients with rheumatoid arthritis.
Coefficient 𝑃
TNF-𝛼 0.388∗ 0.028
IL-1𝛽 0.360∗ 0.043
IL-2 0.398∗ 0.024
IL-4 0.443∗ 0.011
IL-5 0.243 0.180
IL-6 0.380∗ 0.032
IL-7 0.365∗ 0.040
IL-8 0.097 0.599
IL-10 0.439∗ 0.012
IL-12 0.394∗ 0.026
IL-13 0.297 0.099
IL-17 0.123 0.501
G-CSF 0.210 0.248
GM-CSF 0.403∗ 0.022
IFN-𝛾 0.440∗ 0.012
MCP-1 0.353∗ 0.047
MIP-1𝛽 −0.228 0.209
Pearson’s correlation test was used for statistical analysis. ∗𝑃 value less than
0.05.
level showed a significant correlation with IL-4, IL-7, IL-10,
IL-12, and IL-13 levels in RA patients (Table 2).
4. Discussion
IL-37 has emerged as a natural suppressor of innate inflam-
matory and immune responses. It is considered a dual-
function cytokine with intra- and extracellular proper-
ties [7]. It could suppress inflammation and be protec-
tive in several animal models, such as lipopolysaccharide-
induced shock [3], concanavalin A-induced hepatitis [8],
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dextran sulfate sodium- (DSS-) induced colitis [9], hep-
atic ischemia/reperfusion (I/R) injury [10], renal I/R injury
[11], cerebral I/R injury [12], obesity-induced inflammation
and insulin resistance [13], Aspergillus infection [14], and
experimental psoriasis [15]. It is reported to be elevated in
patients with atopic dermatitis [16], chronic HBV infection
[17], Guillain-Barre syndrome [18], acute coronary syn-
drome, Graves’ disease [19], chronic inflammatory bowel
disease [20], and systemic lupus erythematosus [21]. Mean-
while, decreased IL-37 expression was detected in patients
with Vogt-Koyanagi-Harada disease [22], intervertebral disc
degeneration [23], and Behc¸et’s disease [24].
It was found in our study that plasma IL-37 level was
elevated markedly in RA patients, while it was almost
undetectable in the plasma of the healthy controls. In addi-
tion, increased IL-37 in the blood of the RA patients was
positively correlated with the DAS28 disease activity score.
Furthermore, IL-37 level was decreased in the RA patients of
remission as compared with those in the patients with active
RA.These findings are consistent with the data obtained from
50 RA patients in northeast China between 2011 and 2012 in
a recent paper [25], which encourages us to hypothesize that
IL-37 may be a potential biomarker for RA diagnosis, disease
activity assessment, or curative effect observation.
Knowing that TH1/Th2/Th17-related cytokines play criti-
cal roles in the pathogenesis of RA, we detected the multiple
cytokine concentration using a 17-plex test kit. It was found
that, like TNF-𝛼, IL-1𝛽, IL-2, IL-4, IL-6, IL-7, IL-10, IL-
12, GM-CSF, IFN-𝛾, and MCP-1, IL-37 in the blood of
RA patients was also positively correlated with the DAS28
disease activity score, suggesting that both proinflammatory
and anti-inflammatory cytokines are highly produced in
RA patients, especially in those with active RA. As an
anti-inflammatory cytokine, IL-37 could be upregulated by
inflammatory stimuli and cytokines (TLR agonists, IL-1𝛽, IL-
18, TNF-𝛼, and IFN-𝛾).Thus, it is reasonable to speculate that
the proinflammatory cytokines in RA patients may stimulate
IL-37 expression, and IL-37 may mediate a negative feedback
mechanism to suppress excessive proinflammatory cytokines
in RA patients. The elevation of anti-inflammatory cytokines
including IL-37 may be an underlying mechanism to relieve
joint inflammation and disease severity. However, these anti-
inflammatory cytokines may still be too low to neutral-
ize the deleterious effects of proinflammatory cytokines in
progressive RA [26]. The uncontrolled inflammation might
be due to the inadequate antagonism of anti-inflammatory
cytokines against proinflammatory cytokines. This may be
the reason why the anti-inflammatory cytokines including
IL-37 only correlate with disease activity rather than with
disease remission.
It was reported [3] that IL-37 expressing RAW cells
produced higher IL-13 thanmock ones upon LPS stimulation,
and IL-37 transgenic mice produced higher IL-4 than wide
type ones in response to LPS. IL-10 expression was greatly
increased after IL-37 treatment in mice with aspergillosis
[14]. IL-10 secretion was enhanced by LPS challenge in bone
marrow-derived DCs from IL-37 transgenic mice other than
wide type ones [27]. Serum IL-37 was positively correlated
with IL-10 and negatively correlated with IL-12 in patients
with tuberculosis [28]. Both IL-7 and IL-37 were elevated
in patients with COPD compared with nonsmokers [29]. It
was found in our study that IL-37 level exhibited a positive
correlation with cytokines IL-4, IL-7, IL-10, IL-12, and IL-13.
Yet we are not sure whether this is a cause-and-effect relation-
ship (IL-37 stimulating these cytokines or vice versa) or an
accompanying relationship (without any direct relationship
between them; they just all elevate with the progression of the
disease). To the best of our knowledge, the above cytokines
are all involved in the progression of RA. IL-4 [30], IL-10 [31],
and IL-13 [32] could relieve immunological bone destruction
in RA patients. Both exacerbative [33] and suppressive [34]
effects of IL-12 were reported in experimental arthritis. IL-7
is considered an importantmediator in RAdevelopment [35].
Given the correlation between IL-37 and these cytokines,
we suppose that IL-37 may also play an important role in
RA, although experimental studies should be done in our
future studies to examine the detailedmolecularmechanisms
and fully elucidate the regulatory network of IL-37 in RA.
Moreover, the potential role of IL-37 as a biomarker and
pharmacological target of RA also needs to be verified in
larger sample studies.
In conclusion, the plasma concentration of IL-37 was
elevated in patients with RA, especially in those with active
RA. IL-37 level was correlated with the disease activity score,
as well as IL-4, IL-7, IL-10, IL-12, and IL-13 levels in patients
with RA.These findings suggest that IL-37 plays an important
role in the pathogenesis of RA andmay prove to be a potential
biomarker of active RA.
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